302 related articles for article (PubMed ID: 29168011)
1. Pediatric prolactinoma: initial presentation, treatment, and long-term prognosis.
Hoffmann A; Adelmann S; Lohle K; Claviez A; Müller HL
Eur J Pediatr; 2018 Jan; 177(1):125-132. PubMed ID: 29168011
[TBL] [Abstract][Full Text] [Related]
2. Giant, solid, invasive prolactinoma in a prepubescent boy with gynecomastia.
Furtado SV; Saikiran NA; Ghosal N; Hegde AS
Pediatr Neurol; 2010 Jan; 42(1):72-4. PubMed ID: 20004869
[TBL] [Abstract][Full Text] [Related]
3. Broad clinical spectrum and diverse outcomes of prolactinoma with pediatric onset: medication-resistant and recurrent cases.
Kim YM; Seo GH; Kim YM; Choi JH; Yoo HW
Endocr J; 2018 Mar; 65(3):307-315. PubMed ID: 29279457
[TBL] [Abstract][Full Text] [Related]
4. Hyperprolactinemia and prolactinoma.
Romijn JA
Handb Clin Neurol; 2014; 124():185-95. PubMed ID: 25248588
[TBL] [Abstract][Full Text] [Related]
5. Diagnosis, treatment, and outcome of pituitary tumors and other abnormal intrasellar masses. Retrospective analysis of 353 patients.
Gsponer J; De Tribolet N; Déruaz JP; Janzer R; Uské A; Mirimanoff RO; Reymond MJ; Rey F; Temler E; Gaillard RC; Gomez F
Medicine (Baltimore); 1999 Jul; 78(4):236-69. PubMed ID: 10424206
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcome of multimodal therapy for giant prolactinomas.
Andujar-Plata P; Villar-Taibo R; Ballesteros-Pomar MD; Vidal-Casariego A; Pérez-Corral B; Cabezas-Agrícola JM; Álvarez-Vázquez P; Serramito R; Bernabeu I
Endocrine; 2017 Jan; 55(1):231-238. PubMed ID: 27704480
[TBL] [Abstract][Full Text] [Related]
7. Diagnosis and drug therapy of prolactinoma.
Ciccarelli E; Camanni F
Drugs; 1996 Jun; 51(6):954-65. PubMed ID: 8736617
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of surgical and/or medical treatment in patients with prolactinomas during long-term follow-up: a retrospective single-centre study.
Akkus G; Karagun B; Yaldız HN; Evran M; Sert M; Tetiker T
Horm Mol Biol Clin Investig; 2020 Dec; 42(2):153-157. PubMed ID: 34332519
[TBL] [Abstract][Full Text] [Related]
9. MANAGEMENT AND OUTCOMES OF GIANT PROLACTINOMA: A SERIES OF 71 PATIENTS.
Hamidi O; Van Gompel J; Gruber L; Kittah NE; Donegan D; Philbrick KA; Koeller KK; Erickson D; Natt N; Nippoldt TB; Young WF; Bancos I
Endocr Pract; 2019 Apr; 25(4):340-352. PubMed ID: 30995432
[No Abstract] [Full Text] [Related]
10. Diagnostic criteria of small sellar lesions with hyperprolactinemia: Prolactinoma or else.
Cho A; Vila G; Marik W; Klotz S; Wolfsberger S; Micko A
Front Endocrinol (Lausanne); 2022; 13():901385. PubMed ID: 36147567
[TBL] [Abstract][Full Text] [Related]
11. 10-year follow-up study comparing primary medical vs. surgical therapy in women with prolactinomas.
Andereggen L; Frey J; Andres RH; El-Koussy M; Beck J; Seiler RW; Christ E
Endocrine; 2017 Jan; 55(1):223-230. PubMed ID: 27688009
[TBL] [Abstract][Full Text] [Related]
12. Giant Pituitary Adenoma Presenting with Foster-Kennedy Syndrome in a 21-Year Old Ethiopian Patient: A Rarely Reported Phenomenon: A Case Report.
Ayele B; Mengesha A; Wotiye A; Alemayehu Y
Ethiop J Health Sci; 2020 Mar; 30(2):311-314. PubMed ID: 32165821
[TBL] [Abstract][Full Text] [Related]
13. Hyperprolactinemia: pathophysiology and management.
Verhelst J; Abs R
Treat Endocrinol; 2003; 2(1):23-32. PubMed ID: 15871552
[TBL] [Abstract][Full Text] [Related]
14. Surgery combined with dopamine agonists versus dopamine agonists alone in long-term treatment of macroprolactinoma: a retrospective study.
Höfle G; Gasser R; Mohsenipour I; Finkenstedt G
Exp Clin Endocrinol Diabetes; 1998; 106(3):211-6. PubMed ID: 9710362
[TBL] [Abstract][Full Text] [Related]
15. Clinical characteristics of male prolactinoma patients mainly presenting with severe obesity and the metabolic response to dopamine agonist therapy.
Wang L; Wang X; Gong F; Pan H; Zhu H
Front Endocrinol (Lausanne); 2023; 14():1285477. PubMed ID: 38093965
[TBL] [Abstract][Full Text] [Related]
16. Radiation therapy in the multimodal treatment approach of pituitary adenoma.
Becker G; Kocher M; Kortmann RD; Paulsen F; Jeremic B; Müller RP; Bamberg M
Strahlenther Onkol; 2002 Apr; 178(4):173-86. PubMed ID: 12040754
[TBL] [Abstract][Full Text] [Related]
17. Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement.
Petersenn S; Fleseriu M; Casanueva FF; Giustina A; Biermasz N; Biller BMK; Bronstein M; Chanson P; Fukuoka H; Gadelha M; Greenman Y; Gurnell M; Ho KKY; Honegger J; Ioachimescu AG; Kaiser UB; Karavitaki N; Katznelson L; Lodish M; Maiter D; Marcus HJ; McCormack A; Molitch M; Muir CA; Neggers S; Pereira AM; Pivonello R; Post K; Raverot G; Salvatori R; Samson SL; Shimon I; Spencer-Segal J; Vila G; Wass J; Melmed S
Nat Rev Endocrinol; 2023 Dec; 19(12):722-740. PubMed ID: 37670148
[TBL] [Abstract][Full Text] [Related]
18. The Combination of Dopamine Agonist Treatment and Surgery May Be the Best Option in Challenging Prolactinoma Cases: A Single-Centre Experience.
Demir D; Demir AN; Sulu C; Zulfaliyeva G; Cetintas SC; Ozkaya HM; Kadioglu P; Gazioglu N; Tanriover N
World Neurosurg; 2023 Jul; 175():e1166-e1174. PubMed ID: 37120141
[TBL] [Abstract][Full Text] [Related]
19. [Reversible blindness caused by an invasive prolactinoma].
Schöfl-Siegert B; Brabant G; von zur Mühlen A; Schöfl C
Dtsch Med Wochenschr; 2001 May; 126(21):621-4. PubMed ID: 11413749
[TBL] [Abstract][Full Text] [Related]
20. Giant prolactinoma in children and adolescents: a single-center experience and systematic review.
Kumar S; Sarathi V; Lila AR; Sehemby M; Memon SS; Karlekar M; Sankhe S; Patil VA; Shah N; Bandgar T
Pituitary; 2022 Dec; 25(6):819-830. PubMed ID: 35851929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
